ArticleMedComm2026

Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).

Longfeng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.